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Iodochlorhydroxyquin (I) is used in the treatment of 
diaper rash and other skin disorders, and is presumed 
to undergo little or no percutaneous absorption. The 
absorption of (I) from a 3 % cream was studied in 5 
normal male subjects after a single application of the 
cream for 12 h. Plasma levels of the drug were followed 
for 24 h after initial application while urinary excretion 
w as measured for 5 4 h. (I) was extracted from plasma 
and urine and assayed by high-performance liquid chro-
matography. The drug in the range of 0.37-0.56 J.Lg/ml 
was detected in plasma 2 h after application and per-
s isted throughout the treatment period. The mean ex-
cretion rate after 12 h of application was 58.4 J.Lg/h and 
t he excretion rate was 8 .8 J.Lg/h at 42 h posttreatment. 
The elimination rate constant was calculated to be 0.15 
h- 1 • Approximately 40% of the drug was absorbed over 
the 12-h application period. From the above results it is 
a pparent that significant percutaneous absorption of (I) 
occurs. 
Oral use of ha logenated hydroxyquinolines has been severe ly 
restricted in rece n t years beca use ofpo tential neurotox icity [1-
3]. The propo rt ion of a n o ra l dose of halogenated hydroxyqui -
no line whi ch is absorbed is as hi gh as 46% [4 ]. One of the 
ha logenated hydroxyquinolines, iodochlorhydroxyquin (I) , was 
wide ly used for prophylaxis of t raveler 's diarrhea, t he t reatmen t 
of amoebic dysentery, and as a t richomonac ide until investi-
gato rs discove red that it had caused more than 10,000 cases of 
s ubacute mye lo-optic neuropathy (SMON) [1-3,5 ]. 
Hansson [6] found that t he percent recovery of (I) in t he 
urine in normal subjects was 3- 5% of a given oral dose. Tamura 
et a l [1] reported that iron chelated with (1) , a nd this complex 
was exc reted as a gree n pigment in t he urine a nd feces of 
patien ts suffering from SMON. The prese nce of free (I) c rysta ls 
in t h e urine of S MON patients has also been reported [1]. 
Information pertaining to t he percutaneous absorption of (I) 
is exceedingly limited. Prev ious studies have shown t hat suffi -
cient iodine is abso rbed t hrough the skin of patients with a 
variety of dermatoses, resul t ing in fal se ly e levated protein-
bound iod ine a nd t he buta nol-extracted iodine [7,8]. Fischer 
and H a rtvig [9] treated 4 patien ts with widespread dermatitis 
of unstated type with an ointmen t containing 3% (I), and serum 
leve ls of (J) we re estimated by electron capture gas chromatog-
raphy to be 0.8- 1.2 J.Lg/m l. One patient was reported to excrete 
15- 20 mg/day of co njugated drug into the urine [9]. 
(I) is practically insoluble in water, but is soluble in chloro-
fo rm a nd boiling a lcohol [10] . The dissociation constant (pKa) 
of diiodohydroxyquin is 10.15 [11], and as a result of the 
structura l sim ila ri t ies, the pKa of (I) is presumed to be similar. 
The drug is co nsidered to be hi ghly lipid -soluble [3]. 
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Abbreviations: 
HPLC: high-pe rformance liquid chromatography 
(I): iodochlorhydroxyquin 
p Ka: dissoc iation constant 
S MON: subacute myelo-optic neuropathy 
Due to t he widespread use of (I) in t he treatme nt of various 
s kin diseases, its hi gh lipid solubility [3], limi ted percutaneous 
absorption studies, a nd the tox icity associated with oral use, 
the following study was co nducted . 
MATERIALS AND METHODS 
Materials 
Iodochlorhydroxyquin (I) cream 3% (V ioform) was obta ined from 
CIBA Pharmaceuticals (Summit, New Jersey). a-Naphthotlavone was 
purchased from Sigma Chemica l Co. (St. Louis, Missouri). Saran Wrap 
manufactured by Dow Chemical Co. (Indianapolis, Indiana) was pur-
chased locally. In termittent infusion sets, 23 X "!. with 3'12'' tubing, 
were obtained from Abbott Hospital, Inc. (North Chicago, Illinois). 
Evacuated blood collection tubes with lithium heparin were purchased 
from Becton-Dickinson (Rutherford, New Jersey). Heparin sodium lO 
USP units/ ml was obta ined from Elkins-Sinn, Inc. (Cherry Hill. New 
Jersey). All other chemica ls were reagent grade. 
Sample Collection 
Blood and urine (I) levels were determined in 5 healt hy male subjects 
(ages 25-30), weighing 59.4 ± 3.7 kg) . An accurately weighed qua nt ity 
of 5.0 g of a 3% (I) cream was uniformly app lied at 8 AM on the forearm 
over a 200 cm 2 area and occluded with a layer of Saran Wrap and 
wrapped wi th gauze. The cream was applied for 12 h. An intermittent 
infusion set was inserted into t he opposite forearm and blood samples 
were drawn in evacuated collection tubes at 0, 1, 2, 4, 6, 8, 10, 12, and 
24 h. The plasma was separated and frozen until analyzed for (I). 
Patency of the infusion set was insured by filling the tubing with 
heparin sodium (10 uni ts/mil . When each blood sample was collected, 
an aliquot was withdrawn and discarded before 3 ml of blood was 
obtained for ana lys is of (I). Urine samples were collected over the 
fo llowing t ime in te rvals: 0- 3, 3- 6, 6- 9, 9- 12, 12- 24, 24- 27, 27- 30, 48-
51, and 51- 54 h. A drop of toluene was added to each as a preservative, 
and the samples were refrigerated during storage. All blood and urine 
samples were analyzed within 3 days. Preliminary studies indicated 
t hat loss of([) did not occur during storage of plasma or urine samples. 
Assay Methods 
The plasma concentrations of unconjugated (I) were determined by 
high-performance liquid chromatography (HPLC) . A modification of 
our previously reported method 112] was employed. The mobile phase 
for the HPLC system was changed from 20% 0.05 M phosphoric acid 
with 80% methanol to 30% 0.05 M phosphoric ac id and 70% methanol 
to increase the retention time of( !) . In addition, a- naphthotlavone was 
added to all plasma sa mples before analys is as the internal standard. 
Aliquots of 1.0 ml human samples were transferred to 15-ml screw-
capped and Teflon -lined centrifuge tubes. For the preparation of stan -
dard curves, aliquots of (I) standard solutions with an aliquot of the 
internal standard a- naphthotlavone were used to spi ke t he plasma 
samples. After shak ing the tubes for 1 min by hand, 100 11l of concen-
trated perchloric acid was added to each tube. The tubes were vortexed 
for 30 s, and ce ntrifuged at 3000 g (Sorvall RC2-B refrigerated centri -
fuge) for lO min at 15•c. The supernatant fractions were extracted 
twice with 5 ml ethyl ether by vortexing for 10 s, and the phases were 
separated by centrifugi ng for 10 min at 15· c. The prote i11 precipi tates 
were extracted once with 10 ml of ethyl ether by vortexmg for 1 mm, 
and ce ntrifuged as described above. T he ethyl ether extracts w; re dried 
over an hydrous sodium sulfate and evaporated to dryness at 38 C under 
a stream of nitrogen. The residue from eac h fraction was redissolved 
in 250 11 1 of the mobile phase (70% methanol and 30% 0.05 M phosphonc 
acid) and 20 ;d of each was injected onto the column. Plasma samples 
from human subjects t reated topically with (I) were similarly extracted. 
Urine samples wre hydrolyzed according to the procedure of Chen 
et al [1 3]. T he samples were extracted and excretion of total (!) was 
determined by the previously described H PLC method of Ezzedeen r;t 
a! [14] . The recovery of (I) from spiked urine samples was 96.4 ± 2.3% . 
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RESULT S AN D DI SCUSSION 
S ui table reten t ions o f (l) were obtained upon HPLC using 
t he cond it ions desc ribed above. Direct extraction of plasma 
wit h ethyl ethe r wi thout protein precipitatio n wi t h perchloric 
ac id resul ted in t he prese nce of unknown interfering com -
pounds upo n chro matogra phy. La rge a mounts of (I) were found 
to prec ipi t a te wi t h t he plasma proteins [12], a nd therefore t he 
prec ipitated protein fracti ons were ext rac ted a nd used in this 
study. 
F ig lA is a represe n ta tive chro ma tograph o f a n ethyl ether 
extract of a p las ma prote in fraction wi t hout addi t ion o f (l ). A 
chromatograph of plasma to which (I) a nd t he interna l standa rd 
a- naph thofl avone have been added is prese n ted in Fig l B. 
Good sepa ration of (I ) a nd t he in te rna l standa rd wi t hout inter-
fere nce from plasma co nsti t uen ts was ac hieved . The retent ion 
t imes fo r (I ) a nd t he in ternal standa rd we re 7.5 a nd 13.5 min , 
respectively. T he capac ity factor k ' for (I) was 2.94 a nd for t he 
in te rna l standa rd was 6.1. The e lut ion t ime of t he solven t fron t 
was 1.9 min as determined by injecting methanol directly on to 
t he co lumn . 
A standa rd curve was prepa red by extracting the precipita ted 
protein fractio n following the addition of va ri ous concentra -
tions of (l ) to human plasm a (Fig 2). E ach value is the mean 
o f at least 4 sa mpl es wi t h t he st a nda rd deviation. The recovery 
of t he d rug from t he p rotein port ion of plasma was 53%. 
Va lidat io n of t he extraction a nd use of t he precipitated protein 
fract io n of p las ma was published previous ly [12]. A standa rd 
curve fo r (I) di ssolved in t he mobile phase is a lso prese nted in 
F ig 2. . 
T he pe rcuta neous absorp t ion of (I ) in adul t ma le subjects is 
readily demonstrated in Fig 3. Plasma levels of unconjugated 
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FI G l. Extraction of protein precipitate of pl asma blank (A) and of 
plasma co nta in ing 2.5 J.Lg/ml iodochlorhydroxyquin (I ) and 2.0 J.Lg/ml 
in te rnal standard (2) (8 ). Pea k (3) is the solvent front, and peaks (4 ) 
and (5) are unknown mate rials ext rac ted from the plasma. The detector 
was set at 256 nm and 0.002 absorbance units full scale (A U ). Other 
chromatographic condi tions are as described in Materials and Methods. 
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FIG 2. Standard curves of iodochlorhydroxyquin: • - • = Standard 
solut ion diluted wi th 30% 0.05 M phosphoric ac id and 70% methanol. 
• - • = (I ) extrac ted from precipi tate fraction of human plasma. 
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FI G 3. P lasma levels of unconjugated iodochlorhydroxyquin follow· 
ing application of 5 g of a 3% cream to a 200·crn2 area on t he forearm. 
Each value is the mea n ± SO from 5 adult male subjects. A single 
application of t he cream was made and the unabsorbed drug was 
removed after 12 h. 
(I) we re detected 2 h a fte r application , but could not be detected 
wi t hin 1 h. A steady s ta te level was reached a t a proximat.e ly 4 
h . Al t hough t he rema ining topically applied (I ) was rem oved 
a fter 12 h , plasma levels were still e levated 24 h a fte r ini t ial 
application . 
The results demonstrate t hat (1 ) is ra pidly a bso rbed t hrough 
t he skin. The abso rbed (J) passes directly inlo the systemic 
circulation , in co nt rast to (I ) give n ora lly which first passes 
t hrough t he liver. The live r is t he m a in s ite of metabolism , 
convert ing (I ) prima rily to t he glucuronide and sulfa te conju -
gates [3]. As a resu lt of t his difference in reaching the systemic 
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F IG 4. Rate of urinary excretion of tota l iodochlorhydroxyquin a fte r 
topical applica tion of 5 g of a 3% cream. The cream was applied to a 
200-cm 2 a rea on the forearm a nd occluded. Unabsorbed drug was 
removed afte r 12 h. Eac h va lue is t he mea n ± SD from 5 male subjects. 
circulation, high unconjugated plasma levels of (1) after topica l 
use can be expected. Furtherm ore, due to its high lipid solubili ty 
[3 ], unconjugated (I ) in t he adipose tissue of t he skin may 
con t inue to be released to systemic circula t ion long a fter t he 
drug is removed from t he surface of the skin . As a consequence, 
prolonged release of (I) will occur. 
The mean urina ry excretion rates fo r (I) were plotted wit h 
t ime and a re p resen ted in Fig 4. After 12 h of application to 
t he forearm , the total excretion rate for (I) was 58.4 11g/h, while 
t he rate was 8.8 ,,gjh 42 h posttrea tment. Previous studies have 
s hown that ove r 90% of (1 ) which is excreted in t he urine 
fo llowing oral administration is present as the glucuronide a nd 
sulfate conjugates [15]. Therefo re, t he data in Fig 4 were 
obtained from urine samples t hat we re fi rs t hydrolyzed and 
t hen ext racted, giving tota l (I ) exc reted. 
Kinetic data were ca lculated using t he log sigma-minus 
method [16] as plotted in Fig 5. A biphas ic urinary elimination 
of (I) was found to occur. The apparent rate constant {:J was 
calculated from the s lope of t he lower port ion of the plot, while 
t he appa rent rate constant a was calcul ated by t he feat hering 
method as shown in Fig 5 [1 7]. These two rate constants were 
calcul a ted to be 0. 15 and 0.20 h- ', respectively. T he apparent 
half- life for (I) was 4.6 h. 
J ac k a nd Riess [18] have reported as appa ren t half-life of 
11- 14 h fo ll owing t he oral absorpt ion of (I) . Their calculation 
was based on t he measurement of blood levels of unconjugated 
(I). Our va lue of 4.6 h for t he appa rent half-li fe was based on 
total urina ry excretion foll owing percuta neous abso rpt ion. Over 
90% of t he drug is exc reted as conjugates in t he urine. There-
fo re, based on t hese differences, t he resul ts a re not directly 
compa rable. 
Ca lculation of t he percent of t he dose abso rbed was based on 
a n a na lysis of t he drug remaining on t he forearm 12 h after 
application of t he cream [1 9]. The resul ts indicated t hat ove r 
t he 12-h application peri od 40.7 ± 6.5 % of the applied (l) was 
abso rbed. Therefore, approx imately 60 mg of (f) was abso rbed, 
based on t he use of 5 g of a 3% cream. 
P rev ious studies have shown t hat occlusion fac ili tates per-
cutaneous absorption of drugs [20]. A major indication of (I) is 
in diaper dermatit is and di apers constitute a form of occlusion. 
F urt hermore, abso rpt ion through an inflamed dermis occurs 
mo re readily t han t hrough t he normal in tact skin [1 7]. As such, 
a more rapid rate of absorption of (I ) might be expected in a 
child suffering from diaper dermatit is or other related diso rders. 
T he tox icity of (I) administered orally for prolonged peri ods 
of t ime is well known . However, litt le atte ntion has been pa id 
to t he potent ia l tox icity of (I) applied topica lly to la rge body 
su rfaces due to t he presumed lac k of percuta neous abso rpt ion 
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FJG 5. Log s igma- minus plot of r.he urinary exc retion of tota l io-
dochlorhydroxyquin a fte r top ica l application. Each va lue is the mean 
from 5 male subjects. Ua = Sum of the amou nts of drug excreted in 
the urine un t il such t ime as excretion may be conside red to be complete. 
Ut = Cumulat ive amount of drug excreted at a time t. 
of 0 ). We have demonstrated t hat (I) is rap idly abso rbed 
t hrough the skin of hea lt hy adul t males, and due to t he lipid 
so lubility of t he drug, is slowly excreted. T he resul ts uggest 
t hat (I ) should be used only for short per iods of t ime a nd with 
caution when t reating in fa nts suffering from diaper dermatitis 
and other dermatologic di so rders ove r la rge body a reas . 
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